AU2014240467B2 - Regulation of cancer using natural compounds and/or diet - Google Patents

Regulation of cancer using natural compounds and/or diet Download PDF

Info

Publication number
AU2014240467B2
AU2014240467B2 AU2014240467A AU2014240467A AU2014240467B2 AU 2014240467 B2 AU2014240467 B2 AU 2014240467B2 AU 2014240467 A AU2014240467 A AU 2014240467A AU 2014240467 A AU2014240467 A AU 2014240467A AU 2014240467 B2 AU2014240467 B2 AU 2014240467B2
Authority
AU
Australia
Prior art keywords
cancer
tumor
mkd
cell
hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014240467A
Other languages
English (en)
Other versions
AU2014240467A1 (en
Inventor
Loic DELEYROLLE
Brent Reynolds
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida Research Foundation Inc
Original Assignee
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida Research Foundation Inc filed Critical University of Florida Research Foundation Inc
Publication of AU2014240467A1 publication Critical patent/AU2014240467A1/en
Application granted granted Critical
Publication of AU2014240467B2 publication Critical patent/AU2014240467B2/en
Priority to AU2019201369A priority Critical patent/AU2019201369A1/en
Priority to AU2020223647A priority patent/AU2020223647A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/035—Organic compounds containing oxygen as heteroatom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/055—Organic compounds containing sulfur as heteroatom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
AU2014240467A 2013-03-14 2014-03-12 Regulation of cancer using natural compounds and/or diet Ceased AU2014240467B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2019201369A AU2019201369A1 (en) 2013-03-14 2019-02-27 Regulation of cancer using natural compounds and/or diet
AU2020223647A AU2020223647A1 (en) 2013-03-14 2020-08-25 Regulation of cancer using natural compounds and/or diet

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361784386P 2013-03-14 2013-03-14
US61/784,386 2013-03-14
PCT/US2014/023934 WO2014159500A1 (en) 2013-03-14 2014-03-12 Regulation of cancer using natural compounds and/or diet

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019201369A Division AU2019201369A1 (en) 2013-03-14 2019-02-27 Regulation of cancer using natural compounds and/or diet

Publications (2)

Publication Number Publication Date
AU2014240467A1 AU2014240467A1 (en) 2015-11-05
AU2014240467B2 true AU2014240467B2 (en) 2018-11-29

Family

ID=51625178

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2014240467A Ceased AU2014240467B2 (en) 2013-03-14 2014-03-12 Regulation of cancer using natural compounds and/or diet
AU2019201369A Abandoned AU2019201369A1 (en) 2013-03-14 2019-02-27 Regulation of cancer using natural compounds and/or diet
AU2020223647A Abandoned AU2020223647A1 (en) 2013-03-14 2020-08-25 Regulation of cancer using natural compounds and/or diet

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2019201369A Abandoned AU2019201369A1 (en) 2013-03-14 2019-02-27 Regulation of cancer using natural compounds and/or diet
AU2020223647A Abandoned AU2020223647A1 (en) 2013-03-14 2020-08-25 Regulation of cancer using natural compounds and/or diet

Country Status (9)

Country Link
US (2) US20160038456A1 (enExample)
EP (1) EP2968260B1 (enExample)
JP (2) JP6488276B2 (enExample)
CN (2) CN105377252A (enExample)
AU (3) AU2014240467B2 (enExample)
BR (1) BR112015023190A2 (enExample)
CA (1) CA2912518A1 (enExample)
IN (1) IN2015DE09621A (enExample)
WO (1) WO2014159500A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11020372B2 (en) 2015-03-24 2021-06-01 University Of Florida Research Foundation, Incorporated Dietary and natural product management of negative side effects of cancer treatment
JP2018518513A (ja) * 2015-06-26 2018-07-12 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 天然の化合物および／または規定食を用いた炎症の治療方法
CN107921133A (zh) 2015-09-04 2018-04-17 国立大学法人大阪大学 癌症的饮食疗法开发
MY199595A (en) 2016-03-02 2023-11-08 Eisai R&D Man Co Ltd Eribulin-based antibody-drug conjugates and methods of use
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN108192866B (zh) * 2018-03-07 2021-05-11 郑州大学第一附属医院 Sfn联合il-15和il-21制备记忆性t细胞的方法及应用
KR102174166B1 (ko) * 2018-12-13 2020-11-04 영남대학교 산학협력단 호모해링토닌을 유효성분으로 함유하는 세포노화 관련 질환 예방 또는 치료용 조성물
CN110420178B (zh) * 2019-09-11 2022-08-05 长江师范学院 一种胭脂萝卜硫苷水凝胶的制备方法
EP3861992B1 (en) * 2020-02-07 2023-09-06 CannaFamily a.s. Combination therapy comprising plant derived compounds and antineoplastic compounds for treatment of hematological malignancies
AU2020468941A1 (en) * 2020-09-23 2023-03-23 Aminovita S.L. Metabolic cancer therapy
TW202339712A (zh) * 2022-01-24 2023-10-16 國立大學法人大阪大學 用於治療癌症之組合物
CN118259005B (zh) * 2023-12-08 2026-07-17 浙江省肿瘤医院 一种放射性碘难治性分化型甲状腺癌的生物标记物及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012113572A1 (en) * 2011-02-24 2012-08-30 N.V. Nutricia Ketogenic diet composition for the treatment of chemo therapy and/or radiation therapy patients
WO2012122295A2 (en) * 2011-03-07 2012-09-13 Ned Biosystems, Inc. Treatment for pancreatic adenocarcinoma and other cancers of epithelial origin

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5725895B1 (en) * 1995-09-15 2000-10-10 Hopkins J School Of Medicine Method of preparing food product from cruciferous seeds
US6242018B1 (en) * 1997-04-11 2001-06-05 Johns Hopkins School Of Medicine Cancer Chemoprotective food products
JPH1149793A (ja) * 1997-08-08 1999-02-23 Momoya:Kk 野菜由来の抗腫瘍性物質
CN1141092C (zh) * 2001-01-19 2004-03-10 郭兴华 一种防治骨质疏松、癌症和降血脂组合物及其应用
US7968115B2 (en) 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
US20090143433A1 (en) 2004-12-01 2009-06-04 Curt Hendrix Cocktail for modulation of alzheimer's disease
JP2007153834A (ja) * 2005-12-07 2007-06-21 Univ Kansai カイワレ大根由来の不凍活性を有する抽出物、その製造方法、ならびにその用途
JP2011500680A (ja) 2007-10-16 2011-01-06 ジョンズ・ホプキンス・ユニヴァーシティ 放射線傷害から皮膚を保護する方法
US20090252758A1 (en) * 2008-04-07 2009-10-08 Mazed Mohammad A Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance
AR084174A1 (es) 2010-12-21 2013-04-24 Lilly Co Eli Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica
DE102011008016A1 (de) * 2011-01-06 2012-07-12 Johannes F. Coy Schokoladenmasse
DE102011008017A1 (de) 2011-01-06 2012-07-12 Johannes F. Coy Erfrischungsgetränk
WO2012142511A2 (en) 2011-04-15 2012-10-18 Md Matrix Health Llc Dba Md Matrix Health Inc Orthomolecular compositions and their use in stabilizing the extracellular matrix
CA2831403A1 (en) * 2011-05-19 2012-11-22 Glax L.L.C. Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells
GB201210699D0 (en) 2012-06-15 2012-08-01 Vitaflo Ltd Nutritional food
RU2666953C2 (ru) 2012-07-05 2018-09-13 Нутрамакс Лабораториз, Инк. Композиции, содержащие сульфорафан или предшественник сульфорафана и экстракт или порошок молочного чертополоха
US20140275235A1 (en) 2013-03-15 2014-09-18 Loic Pierre Deleyrolle Treatment of Proliferative Disorders
EP2968990A4 (en) 2013-03-15 2016-08-24 Nutramax Lab Inc COMPOSITIONS COMPRISING SULFORAPHANE OR SULFORAPHANE PRECURSOR AND PHYTOSTEROL OR PHYTOSTANOL
BR112015024186B1 (pt) 2013-03-19 2023-05-09 University Of South Florida Composições e métodos para produção de cetose de elevação e manutenção
CN105431159B (zh) 2013-05-14 2020-12-01 马斯公司 关节护理组合物
US20130310457A1 (en) 2013-07-25 2013-11-21 Niral Ramesh Solid-in-oil dispersions
WO2015034812A2 (en) 2013-09-04 2015-03-12 Beth Israel Deaconess Medical Center A new ketogenic diet and its use in treating the critically ill
US11020372B2 (en) 2015-03-24 2021-06-01 University Of Florida Research Foundation, Incorporated Dietary and natural product management of negative side effects of cancer treatment
JP2018518513A (ja) 2015-06-26 2018-07-12 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 天然の化合物および／または規定食を用いた炎症の治療方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012113572A1 (en) * 2011-02-24 2012-08-30 N.V. Nutricia Ketogenic diet composition for the treatment of chemo therapy and/or radiation therapy patients
WO2012122295A2 (en) * 2011-03-07 2012-09-13 Ned Biosystems, Inc. Treatment for pancreatic adenocarcinoma and other cancers of epithelial origin

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ALESSIO PAPI ET AL, "Cytotoxic and Antioxidant Activity of 4-Methylthio-3-butenyl Isothiocyanate from Raphanus sativus L. (Kaiware Daikon) Sprouts", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, (2008-02-01), vol. 56, no. 3, pages 875 - 883. *
CHRISTOPH OTTO ET AL, "Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides", BMC CANCER, (2008-04-30), vol. 8, no. 1, page 122. *
FAROOQI AMMAD AHMAD ET AL, JOURNAL OF EXPERIMENTAL THERAPEUTICS AND ONCOLOGY, vol. 9, no. 3, (2011-01-01), pages 201 - 206. *
KRISTIN W. BARAÑANO ET AL, "The ketogenic diet: Uses in epilepsy and other neurologic illnesses", CURRENT TREATMENT OPTIONS IN NEUROLOGY, (2008-11-01), vol. 10, no. 6, pages 410 - 419. *
MAALOUF M ET AL, "The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies", BRAIN RESEARCH REVIEWS, vol. 59, no. 2, (2009-03-01), pages 293 - 315. *
NATALIE A KELSEY ET AL, "Nutraceutical antioxidants as novel neuroprotective agents", MOLECULES: A JOURNAL OF SYNTHETIC ORGANIC AND NATURAL PRODUCT CHEMISTRY, (2010-11-03), vol. 15, no. 11, pages 7792 - 7814. *
SEYFRIED THOMAS N ET AL, Targeting Energy Metabolism in Brain Cancer with Restricted Diets, GLIOBLASTOMA: MOLECULAR MECHANISMS OF PATHOGENESIS AND CURRENT THERAPEUTIC STRATEGIES, PAGES 341 - 363. (2010-01-01). *

Also Published As

Publication number Publication date
US11666549B2 (en) 2023-06-06
EP2968260A4 (en) 2017-05-10
AU2020223647A1 (en) 2020-09-10
EP2968260A1 (en) 2016-01-20
CN110420329A (zh) 2019-11-08
EP2968260B1 (en) 2020-12-16
JP6488276B2 (ja) 2019-03-20
US20210008024A1 (en) 2021-01-14
WO2014159500A1 (en) 2014-10-02
JP2016514135A (ja) 2016-05-19
CN105377252A (zh) 2016-03-02
US20160038456A1 (en) 2016-02-11
AU2019201369A1 (en) 2019-03-21
CA2912518A1 (en) 2014-10-02
BR112015023190A2 (pt) 2017-07-18
JP2018162248A (ja) 2018-10-18
IN2015DE09621A (en) 2016-02-26
AU2014240467A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
US11666549B2 (en) Regulation of cancer using natural compounds and/or diet
JP2017171683A (ja) Ｒａｇｅ遺伝子発現抑制剤
US12589088B2 (en) Compositions and methods for treating cancer with andrographolide and melatonin combination therapy
KR20240040430A (ko) 아피제닌을 포함하는 대장암 예방 또는 치료용 약학적 조성물
KR101184152B1 (ko) 항산화 단백질 엔알에프-2의 활성 증진, 간염 치료 및 예방 또는 간 보호에 유용한 3, 4-디히드록시벤잘아세톤
CN106999525A (zh) 用于治疗间皮瘤的菜蓟滴定提取物
Kensarah et al. Implementing high Vitamin c treatments to decrease blood uric acid levels in hyperuricemic Saudi patients.
KR101613005B1 (ko) 항암제에 의해 유발되는 신장 독성 질환의 예방 및 치료용 약학적 조성물
Walstad-Terpak Nutrition and Supplements as Chemoprevention for Reducing the Risk of Nonglandular Oral and Oropharyngeal Cancers of the Head and Neck
WO2025096491A1 (en) Phenylacetaldehyde induced apoptosis in colorectal cancer
KR20200134528A (ko) 멜라토닌을 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
Galassetti et al. Effect of Fat Ingestion on Myeloperoxidase; an Exercise Study in Healthy and Obese Children
Gatica et al. Effect of music on 400-m sprint running performance in healthy subjects
Onodera et al. Time Course of VEGF-A mRNA Expression Following Eccentric Contractions in Rat Skeletal Muscle
Stokes et al. No Effect Of Cigarette Smoking On Calf Muscle Size And Density Changes Following Military Training
TORI HUDSON “Dr. Stengler and Dr. Anderson expertly provide clear, practical tools that can possibly save your life or someone close to you. By harnessing the healing power of nature, Outside the Box Cancer Therapies gives the answers to beating cancer naturally.”—MICHAEL T. MURRAY, ND
Gorres et al. Activation of Estrogen Receptor· Potentiates Insulin-stimulated Glucose Uptake into Skeletal Muscle of Female Rats
Reed et al. Foxo Activity is Required for the Normal Muscle Atrophy Program during Cancer Induced Cachexia
Koch et al. Development of Rat Models for Low and High Response to Exercise Training
KIM et al. Mitochondrial Fission Protein Drp1 Plays A Crucial Role For Myotube Differentiation By Regulating Mitochondria-mediated Apoptosis
Koulmann et al. Recovery Of Skeletal Muscle Phenotype After Notexin Injury: Positive Effects Of Running Exercise.
Moore-Harrison et al. Nhlh2 and Lepr Gene Expression in High and Low Physical Activity Mice
Ribeiro et al. Exercise Training Improves Autonomic Function After an Acute Myocardial Infarction
Jackson et al. Brca1 Is Expressed And Binds To Phosphorylated Acetyl Coa Carboxylase In Skeletal Muscle
Kellawan et al. Does Oxygen Delivery Predict Performance During An" All-Out" Critical Power Test?

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired